Which has preferable valuation & earnings, ABC or OBI?

Abcam has higher revenue and earnings than Ondine Biomedical. Ondine Biomedical is trading at a lower price-to-earnings ratio than Abcam, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abcam £350.40M 0.00 N/A £0.06 N/A Ondine Biomedical C$2.05M 3,296.32 -C$424.66K -C$7.00 N/A

Is ABC or OBI more profitable?

Abcam has a net margin of 0.00% compared to Ondine Biomedical's net margin of -1,117.06%. Abcam's return on equity of 0.00% beat Ondine Biomedical's return on equity. Company Net Margins Return on Equity Return on Assets Abcam N/A N/A N/A Ondine Biomedical -1,117.06% -1,411.54% -159.71%

Do analysts recommend OBI or GNS?

Genus has a consensus target price of GBX 3,216.67, indicating a potential upside of 55.24%. Given Genus' stronger consensus rating and higher probable upside, analysts clearly believe Genus is more favorable than Ondine Biomedical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ondine Biomedical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Genus 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has better valuation and earnings, OBI or GNS?

Genus has higher revenue and earnings than Ondine Biomedical. Ondine Biomedical is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ondine Biomedical C$2.05M 3,296.32 -C$424.66K -C$7.00 N/A Genus £672M 2.05 £7.87M £71.00 29.18

Is OBI or GNS more profitable?

Genus has a net margin of 7.07% compared to Ondine Biomedical's net margin of -1,117.06%. Genus' return on equity of 9.70% beat Ondine Biomedical's return on equity. Company Net Margins Return on Equity Return on Assets Ondine Biomedical -1,117.06% -1,411.54% -159.71% Genus 7.07% 9.70% 3.31%

Do analysts prefer OBI or ONT?

Oxford Nanopore Technologies has a consensus price target of GBX 218.60, suggesting a potential upside of 73.63%. Given Oxford Nanopore Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Oxford Nanopore Technologies is more favorable than Ondine Biomedical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ondine Biomedical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Oxford Nanopore Technologies 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80

Does the media prefer OBI or ONT?

In the previous week, Ondine Biomedical had 1 more articles in the media than Oxford Nanopore Technologies. MarketBeat recorded 2 mentions for Ondine Biomedical and 1 mentions for Oxford Nanopore Technologies. Oxford Nanopore Technologies' average media sentiment score of 0.44 beat Ondine Biomedical's score of 0.38 indicating that Oxford Nanopore Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ondine Biomedical 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oxford Nanopore Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate OXB or OBI?

Oxford Biomedica currently has a consensus target price of GBX 604.32, indicating a potential downside of 1.25%. Given Oxford Biomedica's stronger consensus rating and higher probable upside, equities analysts clearly believe Oxford Biomedica is more favorable than Ondine Biomedical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oxford Biomedica 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Ondine Biomedical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media favor OXB or OBI?

In the previous week, Oxford Biomedica and Oxford Biomedica both had 2 articles in the media. Ondine Biomedical's average media sentiment score of 0.38 beat Oxford Biomedica's score of 0.00 indicating that Ondine Biomedical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oxford Biomedica 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ondine Biomedical 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, OBI or ERGO?

Ergomed has higher revenue and earnings than Ondine Biomedical. Ondine Biomedical is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ondine Biomedical C$2.05M 3,296.32 -C$424.66K -C$7.00 N/A Ergomed £152.09M 0.00 £15M £0.29 N/A

Is OBI or ERGO more profitable?

Ergomed has a net margin of 9.87% compared to Ondine Biomedical's net margin of -1,117.06%. Ergomed's return on equity of 18.08% beat Ondine Biomedical's return on equity. Company Net Margins Return on Equity Return on Assets Ondine Biomedical -1,117.06% -1,411.54% -159.71% Ergomed 9.87% 18.08% 10.16%

Ondine Biomedical (OBI) Competitors

C$13.00 +0.45 (+3.59%)

As of 04:10 PM Eastern

Compare

OBI vs. ABC, GNS, ONT, OXB, and ERGO

Should you buy Ondine Biomedical stock or one of its competitors? MarketBeat compares Ondine Biomedical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ondine Biomedical include Abcam (ABC), Genus (GNS), Oxford Nanopore Technologies (ONT), Oxford Biomedica (OXB), and Ergomed (ERGO). These companies are all part of the "biotechnology" industry.

How does Ondine Biomedical compare to Abcam?

Abcam (LON:ABC) and Ondine Biomedical (LON:OBI) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

Abcam has a net margin of 0.00% compared to Ondine Biomedical's net margin of -1,117.06%. Abcam's return on equity of 0.00% beat Ondine Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abcam	N/A	N/A	N/A
Ondine Biomedical	-1,117.06%	-1,411.54%	-159.71%

In the previous week, Ondine Biomedical had 2 more articles in the media than Abcam. MarketBeat recorded 2 mentions for Ondine Biomedical and 0 mentions for Abcam. Ondine Biomedical's average media sentiment score of 0.38 beat Abcam's score of 0.00 indicating that Ondine Biomedical is being referred to more favorably in the news media.

Company	Overall Sentiment
Abcam	Neutral
Ondine Biomedical	Neutral

29.3% of Ondine Biomedical shares are held by institutional investors. 37.4% of Ondine Biomedical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Abcam has higher revenue and earnings than Ondine Biomedical. Ondine Biomedical is trading at a lower price-to-earnings ratio than Abcam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abcam	£350.40M	0.00	N/A	£0.06	N/A
Ondine Biomedical	C$2.05M	3,296.32	-C$424.66K	-C$7.00	N/A

Summary

Abcam beats Ondine Biomedical on 6 of the 10 factors compared between the two stocks.

How does Ondine Biomedical compare to Genus?

Ondine Biomedical (LON:OBI) and Genus (LON:GNS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk.

In the previous week, Ondine Biomedical had 2 more articles in the media than Genus. MarketBeat recorded 2 mentions for Ondine Biomedical and 0 mentions for Genus. Ondine Biomedical's average media sentiment score of 0.38 beat Genus' score of 0.00 indicating that Ondine Biomedical is being referred to more favorably in the media.

Company	Overall Sentiment
Ondine Biomedical	Neutral
Genus	Neutral

Ondine Biomedical has a beta of 0.273, suggesting that its share price is 73% less volatile than the broader market. Comparatively, Genus has a beta of 0.896, suggesting that its share price is 10% less volatile than the broader market.

29.3% of Ondine Biomedical shares are owned by institutional investors. Comparatively, 52.9% of Genus shares are owned by institutional investors. 37.4% of Ondine Biomedical shares are owned by insiders. Comparatively, 0.7% of Genus shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Genus has a consensus target price of GBX 3,216.67, indicating a potential upside of 55.24%. Given Genus' stronger consensus rating and higher probable upside, analysts clearly believe Genus is more favorable than Ondine Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ondine Biomedical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Genus	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Genus has higher revenue and earnings than Ondine Biomedical. Ondine Biomedical is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ondine Biomedical	C$2.05M	3,296.32	-C$424.66K	-C$7.00	N/A
Genus	£672M	2.05	£7.87M	£71.00	29.18

Genus has a net margin of 7.07% compared to Ondine Biomedical's net margin of -1,117.06%. Genus' return on equity of 9.70% beat Ondine Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ondine Biomedical	-1,117.06%	-1,411.54%	-159.71%
Genus	7.07%	9.70%	3.31%

Summary

Genus beats Ondine Biomedical on 12 of the 16 factors compared between the two stocks.

How does Ondine Biomedical compare to Oxford Nanopore Technologies?

Ondine Biomedical (LON:OBI) and Oxford Nanopore Technologies (LON:ONT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

Oxford Nanopore Technologies has a net margin of -64.85% compared to Ondine Biomedical's net margin of -1,117.06%. Oxford Nanopore Technologies' return on equity of -29.43% beat Ondine Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ondine Biomedical	-1,117.06%	-1,411.54%	-159.71%
Oxford Nanopore Technologies	-64.85%	-29.43%	-14.42%

In the previous week, Ondine Biomedical had 1 more articles in the media than Oxford Nanopore Technologies. MarketBeat recorded 2 mentions for Ondine Biomedical and 1 mentions for Oxford Nanopore Technologies. Oxford Nanopore Technologies' average media sentiment score of 0.44 beat Ondine Biomedical's score of 0.38 indicating that Oxford Nanopore Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ondine Biomedical	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oxford Nanopore Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oxford Nanopore Technologies has a consensus price target of GBX 218.60, suggesting a potential upside of 73.63%. Given Oxford Nanopore Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Oxford Nanopore Technologies is more favorable than Ondine Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ondine Biomedical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Ondine Biomedical has a beta of 0.273, suggesting that its stock price is 73% less volatile than the broader market. Comparatively, Oxford Nanopore Technologies has a beta of 0.914, suggesting that its stock price is 9% less volatile than the broader market.

Ondine Biomedical has higher earnings, but lower revenue than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Ondine Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ondine Biomedical	C$2.05M	3,296.32	-C$424.66K	-C$7.00	N/A
Oxford Nanopore Technologies	£223.90M	5.47	-£175.21M	-£15.10	N/A

29.3% of Ondine Biomedical shares are owned by institutional investors. Comparatively, 19.6% of Oxford Nanopore Technologies shares are owned by institutional investors. 37.4% of Ondine Biomedical shares are owned by insiders. Comparatively, 2.5% of Oxford Nanopore Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Oxford Nanopore Technologies beats Ondine Biomedical on 9 of the 16 factors compared between the two stocks.

How does Ondine Biomedical compare to Oxford Biomedica?

Oxford Biomedica (LON:OXB) and Ondine Biomedical (LON:OBI) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Oxford Biomedica has a net margin of -17.85% compared to Ondine Biomedical's net margin of -1,117.06%. Oxford Biomedica's return on equity of -48.56% beat Ondine Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-17.85%	-48.56%	-12.67%
Ondine Biomedical	-1,117.06%	-1,411.54%	-159.71%

Oxford Biomedica currently has a consensus target price of GBX 604.32, indicating a potential downside of 1.25%. Given Oxford Biomedica's stronger consensus rating and higher probable upside, equities analysts clearly believe Oxford Biomedica is more favorable than Ondine Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Ondine Biomedical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

32.4% of Oxford Biomedica shares are owned by institutional investors. Comparatively, 29.3% of Ondine Biomedical shares are owned by institutional investors. 43.3% of Oxford Biomedica shares are owned by insiders. Comparatively, 37.4% of Ondine Biomedical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Oxford Biomedica and Oxford Biomedica both had 2 articles in the media. Ondine Biomedical's average media sentiment score of 0.38 beat Oxford Biomedica's score of 0.00 indicating that Ondine Biomedical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oxford Biomedica	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ondine Biomedical	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ondine Biomedical has lower revenue, but higher earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Ondine Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£168.74M	4.39	-£143.51M	-£26.92	N/A
Ondine Biomedical	C$2.05M	3,296.32	-C$424.66K	-C$7.00	N/A

Oxford Biomedica has a beta of 1.096, indicating that its stock price is 10% more volatile than the broader market. Comparatively, Ondine Biomedical has a beta of 0.273, indicating that its stock price is 73% less volatile than the broader market.

Summary

Oxford Biomedica beats Ondine Biomedical on 10 of the 15 factors compared between the two stocks.

How does Ondine Biomedical compare to Ergomed?

Ondine Biomedical (LON:OBI) and Ergomed (LON:ERGO) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

Ergomed has a net margin of 9.87% compared to Ondine Biomedical's net margin of -1,117.06%. Ergomed's return on equity of 18.08% beat Ondine Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ondine Biomedical	-1,117.06%	-1,411.54%	-159.71%
Ergomed	9.87%	18.08%	10.16%

29.3% of Ondine Biomedical shares are owned by institutional investors. Comparatively, 71.1% of Ergomed shares are owned by institutional investors. 37.4% of Ondine Biomedical shares are owned by insiders. Comparatively, 18.2% of Ergomed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Ondine Biomedical has a beta of 0.273, suggesting that its stock price is 73% less volatile than the broader market. Comparatively, Ergomed has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market.

In the previous week, Ondine Biomedical had 2 more articles in the media than Ergomed. MarketBeat recorded 2 mentions for Ondine Biomedical and 0 mentions for Ergomed. Ondine Biomedical's average media sentiment score of 0.38 beat Ergomed's score of 0.00 indicating that Ondine Biomedical is being referred to more favorably in the media.

Company	Overall Sentiment
Ondine Biomedical	Neutral
Ergomed	Neutral

Ergomed has higher revenue and earnings than Ondine Biomedical. Ondine Biomedical is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ondine Biomedical	C$2.05M	3,296.32	-C$424.66K	-C$7.00	N/A
Ergomed	£152.09M	0.00	£15M	£0.29	N/A

Summary

Ergomed beats Ondine Biomedical on 9 of the 12 factors compared between the two stocks.

Get Ondine Biomedical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OBI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OBI vs. The Competition

Export

Metric	Ondine Biomedical	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	C$6.75B	C$445.28M	C$6.64B	C$2.71B
Dividend Yield	N/A	3.86%	2.67%	6.16%
P/E Ratio	-1.86	3.12	24.75	366.28
Price / Sales	3,296.32	6,656.31	508.64	86,890.05
Price / Cash	1.99	13.13	42.36	27.85
Price / Book	1,505.56	87.10	10.47	7.71
Net Income	-C$424.66K	-C$96.07M	C$3.56B	C$5.89B
7 Day Performance	-13.33%	-2.17%	-1.11%	-0.75%
1 Month Performance	-9.97%	0.17%	1.28%	1.84%
1 Year Performance	44.44%	53.58%	21.20%	71.71%

Ondine Biomedical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OBI Ondine Biomedical	N/A	C$13.00 +3.6%	N/A	+37.5%	C$6.75B	C$2.05M	N/A	N/A	Gap Up
ABC Abcam	N/A	N/A	N/A	N/A	£2.81B	£350.40M	20,433.33	1,650	Gap Up High Trading Volume
GNS Genus	2.606 of 5 stars	GBX 2,274 flat	GBX 3,216.67 +41.5%	+12.4%	£1.51B	£672M	32.03	480	Gap Down
ONT Oxford Nanopore Technologies	2.6486 of 5 stars	GBX 133.52 -4.6%	GBX 218.60 +63.7%	+9.1%	£1.30B	£223.90M	N/A	1,281
OXB Oxford Biomedica	0.8428 of 5 stars	GBX 630 +5.0%	GBX 604.32 -4.1%	+82.0%	£761.79M	£168.74M	N/A	891

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:OBI) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ondine Biomedical (OBI) Competitors

OBI vs. ABC, GNS, ONT, OXB, and ERGO

How does Ondine Biomedical compare to Abcam?

Summary

How does Ondine Biomedical compare to Genus?

Summary

How does Ondine Biomedical compare to Oxford Nanopore Technologies?

Summary

How does Ondine Biomedical compare to Oxford Biomedica?

Summary

How does Ondine Biomedical compare to Ergomed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBI vs. The Competition

Ondine Biomedical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ondine Biomedical (OBI) Competitors

OBI vs. ABC, GNS, ONT, OXB, and ERGO

How does Ondine Biomedical compare to Abcam?

Is ABC or OBI more profitable?

Does the media refer more to ABC or OBI?

Do insiders & institutionals hold more shares of ABC or OBI?

Which has preferable valuation & earnings, ABC or OBI?

Summary

How does Ondine Biomedical compare to Genus?

Does the media prefer OBI or GNS?

Which has more risk and volatility, OBI or GNS?

Do institutionals and insiders have more ownership in OBI or GNS?

Do analysts recommend OBI or GNS?

Which has better valuation and earnings, OBI or GNS?

Is OBI or GNS more profitable?

Summary

How does Ondine Biomedical compare to Oxford Nanopore Technologies?

Is OBI or ONT more profitable?

Does the media prefer OBI or ONT?

Do analysts prefer OBI or ONT?

Which has more volatility and risk, OBI or ONT?

Which has preferable earnings & valuation, OBI or ONT?

Do institutionals & insiders hold more shares of OBI or ONT?

Summary

How does Ondine Biomedical compare to Oxford Biomedica?

Is OXB or OBI more profitable?

Do analysts rate OXB or OBI?

Do institutionals and insiders believe in OXB or OBI?

Does the media favor OXB or OBI?

Which has better earnings and valuation, OXB or OBI?

Which has more volatility and risk, OXB or OBI?

Summary

How does Ondine Biomedical compare to Ergomed?

Is OBI or ERGO more profitable?

Do institutionals & insiders believe in OBI or ERGO?

Which has more risk & volatility, OBI or ERGO?

Does the media prefer OBI or ERGO?

Which has preferable valuation & earnings, OBI or ERGO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBI vs. The Competition

Ondine Biomedical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools